Can Zopiclone Induce Delirium?
Yes, zopiclone can induce delirium in older adults, and this risk is particularly elevated in elderly patients, those with dementia, and individuals who abruptly discontinue the medication after chronic use.
Mechanism and Risk Profile
Zopiclone, like other nonbenzodiazepine hypnotics (Z-drugs), shares pharmacologic properties with benzodiazepines despite its different chemical structure 1. The FDA labeling for eszopiclone (the active S-enantiomer of zopiclone) explicitly warns about cognitive and behavioral changes that may be serious or life-threatening 2. These medications are associated with confusion, disorientation, and memory impairment—all cardinal features of delirium.
Evidence for Delirium Induction
Direct Delirium Risk
- Case reports document delirium after even a single dose of zopiclone in an 84-year-old patient 3, demonstrating that susceptible individuals can develop delirium with minimal exposure
- The NICE delirium prevention guideline specifically identifies benzodiazepines and similar agents as potentially associated with delirium 4, leading to reluctance to recommend pharmacologic sleep enhancers in at-risk populations
Withdrawal-Induced Delirium
- Abrupt discontinuation poses significant risk: A case report documented severe delirium in an elderly patient following abrupt zopiclone withdrawal, which completely resolved when the medication was resumed at lower doses 5
- This mirrors findings with zolpidem, where abrupt cessation after chronic high-dose use resulted in acute delirium requiring benzodiazepine treatment 6
High-Risk Populations
The following groups face substantially elevated delirium risk:
- Older adults (especially those ≥65 years): Glass and colleagues demonstrated a 5-fold increase in memory loss, confusion, and disorientation with sedative-hypnotics in older patients with insomnia 2
- Patients with dementia: In a randomized trial of AD patients, 3 participants discontinued zopiclone due to intense daytime sedation and worsened agitation 7
- Those with baseline cognitive impairment or multiple risk factors for delirium
Clinical Implications and Recommendations
Prescribing Considerations
When zopiclone must be used despite delirium risk:
- Start with the lowest effective dose and monitor closely for cognitive changes
- Avoid in patients with multiple delirium risk factors (advanced age, dementia, polypharmacy, acute illness)
- Never discontinue abruptly in patients on chronic therapy—taper gradually to prevent withdrawal delirium 8
- Limit duration: FDA approval is for short-term use, though many prescribe long-term despite lack of evidence 2
Monitoring
Watch specifically for:
- Acute confusion or disorientation
- Fluctuating consciousness
- Increased agitation or behavioral disturbances
- Next-morning cognitive impairment
- Paradoxical worsening of sleep or daytime function
When Delirium Occurs
If delirium develops:
- Do not abruptly stop if patient has been on chronic therapy
- Consider gradual taper with benzodiazepine bridge if withdrawal suspected 5
- Evaluate for other precipitating factors (infection, metabolic derangement, other medications)
- In acute withdrawal delirium, benzodiazepines (e.g., lorazepam) may be required for stabilization 6
Important Caveats
The FDA label notes that zopiclone/eszopiclone can cause amnesia, confusion, and complex behaviors (sleep-driving, preparing food) while not fully awake 1. These effects are amplified by alcohol or other CNS depressants 1. The risk-benefit calculation becomes particularly unfavorable in older adults where observational data suggest associations with falls, fractures, and increased mortality 2.
The bottom line: Zopiclone definitively can cause delirium both through direct CNS effects and withdrawal, making it a poor choice for older adults and those with cognitive impairment where safer alternatives should be prioritized.